Prevention, Diagnosis and Treatment of Hematologic Diseases
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 267
Special Issue Editor
Interests: lymphoproliferative diseases; non-Hodgkin's lymphoma; chronic lymphocytic leukemia; target therapy; immunotherapy; checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological malignancies are a heterogeneous group of rare diseases with different impairments of blood, bone marrow, and organ-associated diseases with highly variable prognoses. The incidence is around 1.2 million new cases each year worldwide. Leukemias, lymphomas, myeloma, and proliferative diseases, as lymphoproliferative or myeloproliferative diseases, represent the major groups of interest. With the advent of precision medicine, all subgroups of disease show deep and very different mechanisms of diagnosis, treatment, and prognosis. A plethora of drugs or drug combinations, including chemotherapy, small molecule inhibitors targeting cellular oncoproteins, immunotherapies, immune checkpoint inhibitors, and CAR-T cells (chimeric antigen receptor-T cells) have significantly improved the management of patients.
This Special Issue of the Journal of Personalized Medicine, named “Prevention, Diagnosis and Treatment of Hematologic Diseases”, aims to highlight the current state of the art of hematological malignances, with no restriction on the type of diseases, but with the aim of offering a sound overview on different types of diseases. Attention will be focused on precision medicine approaches, in terms of molecular biology analyses, immunohistochemistry or cytogenetic features in the setting of diagnosis and in monitoring, and in terms of target therapy in the setting of treatment.
Original research articles and reviews focusing on these topics will be included in this Special Issue.
Dr. Maura Nicolos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-hodgkin lymphoma
- hodgkin lymphoma
- chronic lymphocytic leukemia
- chronic myeloid leukemia
- myeloproliferative disease
- acute leukemia
- multiple myeloma
- molecular biology
- cytogenetics
- target therapy
- checkpoint inhibitors
